Izcovich Ariel, Cuker Adam, Kunkle Robert, Neumann Ignacio, Panepinto Julie, Pai Menaka, Seftel Matthew, Cheung Matthew C, Lottenberg Richard, Byrne Michael, Plovnick Robert, Terrell Deirdra, Holter-Chakrabarty Jennifer L, Djulbegovic Benjamin, Hicks Lisa K, Wiercioch Wojtek, Nieuwlaat Robby, Schünemann Holger J
Department of Internal Medicine, German Hospital, Buenos Aires, Argentina.
Department of Medicine and.
Blood Adv. 2020 May 12;4(9):2095-2110. doi: 10.1182/bloodadvances.2020001755.
Since November 2018, Blood Advances has published American Society of Hematology (ASH) clinical practice guidelines on venous thromboembolism, immune thrombocytopenia, and sickle cell disease. More ASH guidelines on these and other topics are forthcoming. These guidelines have been developed using consistent processes, methods, terminology, and presentation formats. In this article, we describe how patients, clinicians, policymakers, researchers, and others may use ASH guidelines and the many related derivates by describing how to interpret information and how to apply it to clinical decision-making. Also, by exploring how these documents are developed, we aim to clarify their limitations and possible inappropriate usage.
自2018年11月以来,《血液进展》已发表了美国血液学会(ASH)关于静脉血栓栓塞、免疫性血小板减少症和镰状细胞病的临床实践指南。关于这些及其他主题的更多ASH指南即将发布。这些指南是使用一致的流程、方法、术语和呈现格式制定的。在本文中,我们通过描述如何解释信息以及如何将其应用于临床决策,来阐述患者、临床医生、政策制定者、研究人员及其他人员如何使用ASH指南及许多相关衍生资料。此外,通过探讨这些文件的制定方式,我们旨在阐明其局限性及可能的不当用法。